{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=7", "query": { "condition": "Advanced Solid Tumour", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 3366, "total_pages": 337, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T04:41:44.275Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Solid Tumors" ], "interventions": [ { "name": "SBT6050", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silverback Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-07-27", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460456" }, { "nct_id": "NCT00003331", "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "1998-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003331" }, { "nct_id": "NCT04439253", "title": "Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Crizotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2015-08-12", "completion_date": "2027-03-17", "has_results": true, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439253" }, { "nct_id": "NCT07262619", "title": "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "MSI-H or dMMR Advanced Solid Tumors", "MSI-H/dMMR Gastric Cancer", "MSI-H/dMMR Colorectal Cancer", "MSI-H/dMMR Gastroesophageal-junction Cancer", "Endometrial Cancer", "Mismatch Repair Deficient or MSI-High Solid Tumors" ], "interventions": [ { "name": "EIK1005", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA® )", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-01-20", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 10, "location_summary": "Los Angeles, California • Doral, Florida • Hialeah, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Tamarac", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07262619" }, { "nct_id": "NCT06835569", "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "PDAC - Pancreatic Ductal Adenocarcinoma", "NSCLC (Non-small Cell Lung Cancer)", "CRC (Colorectal Cancer)", "Advanced Solid Tumors" ], "interventions": [ { "name": "ALTA3263", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin /Carboplatin", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "GnP", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alterome Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2025-03-05", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 12, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06835569" }, { "nct_id": "NCT00019539", "title": "Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Renal Cell Cancer", "Recurrent Renal Cell Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-11", "completion_date": "2004-11", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019539" }, { "nct_id": "NCT00054977", "title": "Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Lung Cancer", "Breast Cancer", "Head and Neck Cancer", "Prostate Cancer" ], "interventions": [ { "name": "GM-CT-01", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galectin Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2003-02", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2012-03-12", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 4, "location_summary": "Jacksonville, Florida • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054977" }, { "nct_id": "NCT06540066", "title": "A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumor", "Metastatic Cancer", "Metastatic Solid Tumor" ], "interventions": [ { "name": "BGB-B3227", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2024-09-11", "completion_date": "2026-01-09", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 5, "location_summary": "Los Angeles, California • St Louis, Missouri • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06540066" }, { "nct_id": "NCT02081495", "title": "A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "DOXIL/CAELYX reference product (Treatment A)", "type": "DRUG" }, { "name": "DOXIL/CAELYX test product (Treatment B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-08", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2016-11-11", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02081495" }, { "nct_id": "NCT04613492", "title": "A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "MEDI9253", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 40, "start_date": "2020-12-02", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-10-15T04:41:44.275Z", "location_count": 5, "location_summary": "St Louis, Missouri • Buffalo, New York • New York, New York + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04613492" } ] }